CopperNostics—Here We Are Now, Entertain Us!

Read full text
Authors: Santiago Andrés Brühlmann, Martin Walther, Klaus Kopka, Martin Kreller, Oliver Kiss
Cited by: 6
References: 288

Abstract

Diagnosis and endoradiotherapy using copper radioisotopes—defined as Theranostics or, more specifically, CopperNostics—have the potential to play a prominent role in modern precision medicine, as demonstrated by the FDA approval of [64Cu]Cu-DOTA-TATE (Detectnet). In this review we highlight current developments in the production, radiochemical purification, quality control, availability, logistics, and regulatory hurdles of the most relevant copper radioisotopes, 60Cu, 61Cu, 62Cu, 64Cu, and 67Cu, for nuclear medicine. Radiopharmaceuticals based on their application in registered clinical trials, either as molecular imaging agents, companion diagnostics or therapeutic agents, are also presented addressing unmet medical needs.

Fields of Study & Subjects

Radiopharmaceutical Chemistry and Applications Medical Imaging Techniques and Applications Boron Compounds in Chemistry

Publication details

Journal / source
Pharmaceuticals
Publisher
MDPI AG
Volume
19
Issue
2
Pages
321–321
Publication date
15 February 2026
Language
EN